Biohaven Pharmaceutical (NYSE:BHVN) focuses on developing innovative therapies for debilitating neurological and neuropsychiatric diseases, including rare disorders. The company's research and development efforts are primarily concentrated on advancing a pipeline of novel compounds targeting key pathways involved in a range of central nervous system disorders. With several projects in clinical trials, Biohaven is committed to bringing new treatments to market that address unmet medical needs. Its objective is to improve the lives of patients suffering from serious conditions by harnessing the power of cutting-edge science. As of my last update, Biohaven Pharmaceutical is solely listed on the New York Stock Exchange under the ticker symbol (NYSE:BHVN), with a strong dedication to excellence in all aspects of its operations from research to patient care.